{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:13Z","timestamp":1794360493340,"version":"4.9.0"},"reference-count":107,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"No funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/13543784.2024.2313105","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T22:54:22Z","timestamp":1706655262000},"page":"201-217","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Duchenne muscular dystrophy: promising early-stage clinical trials to watch"],"prefix":"10.1080","volume":"33","author":[{"given":"Annie","family":"Tang","sequence":"first","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528962"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0631-3"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-022-01138-2"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210678"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805263182104"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101366"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140048"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00291610"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1180"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.6030\/1939-067X-3.1.19"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774519872702"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29575"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210743"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.05.013"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.68.5.632"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2408-9"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218683"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26161"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012910"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00613-8"},{"key":"e_1_3_4_25_1","first-page":"9","article-title":"Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy","volume":"31","author":"Angelini C","year":"2012","unstructured":"Angelini C, Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 2012;31:9\u201315.","journal-title":"Acta Myol"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13071241"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0075-7"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2016.28"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2016.152"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01512-2"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0657-1"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01267-2"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01339-3"},{"key":"e_1_3_4_34_1","unstructured":"Dyne Therapeutics. Dyne therapeutics receives FDA fast track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy. Dyne Therapeutics [Internet]. 2022 Oct 31 [cited 2023 Aug 12]; Available from: https:\/\/investors.dyne-tx.com\/news-releases\/news-release-details\/dyne-therapeutics-receives-fda-fast-track-designation-dyne-251"},{"key":"e_1_3_4_35_1","unstructured":"Delivering on the RNA Revolution [internet]. Avidity Biosciences. 2023 [cited 2023 Aug 1]. Available from: https:\/\/www.aviditybiosciences.com\/pipeline\/dmd\/"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0845"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020320"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221648"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6020051"},{"key":"e_1_3_4_40_1","volume-title":"PepGen reports positive data from phase 1 trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy","author":"PepGen","unstructured":"PepGen. PepGen reports positive data from phase 1 trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy. Boston: PepGen; 2022."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203724"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203955"},{"key":"e_1_3_4_43_1","unstructured":"PepGen. PepGen announces clearance by health Canada of CTA for PGN-EDO51 to begin the phase 2 clinical trial CONNECT1-EDO51 for the treatment of Duchenne muscular dystrophy. BioSpace. [cited 2024 Feb 05]. Available from: https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-announces-clearance-health-canada-cta-pgn-edo51-begin"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03184-z"},{"key":"e_1_3_4_45_1","unstructured":"Sarepta Therapeutics. Sarepta therapeutics announces that FDA has lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy. Globe Newswire [Internet]. 2022 Sep [cited 2023 Aug 12]; Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.0c00478"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00008"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.6b00226"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030778"},{"key":"e_1_3_4_50_1","unstructured":"Keown A FDA places clinical hold on entrada\u2019s IND for Duchenne muscular dystrophy [internet]. Biospace. 2022 [cited 2023 Oct 21]. Available from: https:\/\/www.biospace.com\/article\/fda-places-clinical-hold-on-entrada-s-ind-for-duchenne-muscular-dystrophy-\/"},{"key":"e_1_3_4_51_1","unstructured":"Entrada therapeutics. Entrada therapeutics receives authorization in the United Kingdom to initiate phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy [internet]. CureDuchenne. 2023 [cited 2023 Oct 21]. Available from: https:\/\/cureduchenne.org\/research\/entrada-dmd\/"},{"key":"e_1_3_4_52_1","unstructured":"MacDonald K. Entrada therapeutics announces first participant dosed in its phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy [internet]. Biospace. 2023 [cited 2023 Oct 21]. Available from: https:\/\/www.biospace.com\/article\/releases\/entrada-therapeutics-announces-first-participant-dosed-in-its-phase-1-clinical-trial-of-entr-601-44-for-the-potential-treatment-of-duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.07.239"},{"key":"e_1_3_4_54_1","unstructured":"Nippon Shinyaku Co. Ltd. FDA grants breakthrough therapy designation to NS-089\/NCNP-02 for the treatment of Duchenne muscular dystrophy. Nippon Shinyaku Co Ltd [Internet]. [cited 2023 Jul 28]. Available from: https:\/\/www.ncnp.go.jp\/topics\/2022\/20220317e.html"},{"key":"e_1_3_4_55_1","unstructured":"Camusat A. SQY therapeutics \u2013 the \u201cavance 1\u201d clinical trial \u2013 Duchenne muscular dystrophy [internet]. SQY Therapeutics. 2023 [cited 2023 Aug 7]. Available from: https:\/\/sqy-therapeutics.com\/en\/sqy-therapeutics-avance-1-duchenne-muscular-dystrophy-home\/."},{"key":"e_1_3_4_56_1","unstructured":"Meglio M. Duchenne Agent WVE-N531 Shows Targeted Exon Skipping in Phase 1\/2 Study. Neurology Live [Internet]. 2022 Dec 20 [cited 2023 Aug 12]. Available from: https:\/\/www.neurologylive.com\/view\/duchenne-agent-wve-n531-shows-targeted-exon-skipping-phase-1-2-study"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.286"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859930"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.09.008"},{"key":"e_1_3_4_60_1","unstructured":"Parent Project Muscular Dystrophy. Astellas gene therapies announces plans to discontinue development of duchenne gene therapy programs [Internet]. Parent Project Muscular Dystrophy. 2022 [cited 2023 Oct 21]. Available from: https:\/\/www.parentprojectmd.org\/astellas-gene-therapies-announces-plans-to-discontinue-development-of-duchenne-gene-therapy-programs\/"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2212912"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2024.01.003"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307798"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2016.001"},{"key":"e_1_3_4_65_1","volume-title":"Parent Project Muscular Dystrophy 2021 Virtual Annual Conference [Internet]","author":"Danos O","year":"2021","unstructured":"Danos O. In the pipeline: pre-clinical gene therapy- REGENXBIO - RGX-202: an investigational gene therapy for Duchenne muscular dystrophy (DMD). Parent Project Muscular Dystrophy 2021 Virtual Annual Conference [Internet]. 2021 [cited 2023 Aug 20]. Available from: https:\/\/www.parentprojectmd.org\/drug-development-pipeline\/rgx-202\/"},{"key":"e_1_3_4_66_1","volume-title":"Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]","author":"Binks M","year":"2019","unstructured":"Binks M. Pfizer presents at the parent project muscular dystrophy 2019 annual conference. Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]. 2019 [cited 2023 Aug 20]. Available from: http:\/\/www.parentprojectmd.org\/drug-development-pipeline\/pf-06939926-mini-dystrophin-gene-therapy\/"},{"key":"e_1_3_4_67_1","volume-title":"Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]","author":"Laforet G","year":"2019","unstructured":"Laforet G. Solid biosciences presents at the parent project muscular dystrophy 2019 annual conference. Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]. Orlando, FLorida: Parent Project Muscular Dystrophy; 2019 [cited 2023 Aug 20]. Available from: https:\/\/www.parentprojectmd.org\/drug-development-pipeline\/pf-06939926-mini-dystrophin-gene-therapy\/"},{"key":"e_1_3_4_68_1","volume-title":"Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]","author":"Ingram D","year":"2019","unstructured":"Ingram D. Sarepta presents at the parent project muscular dystrophy 2019 annual conference. Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]. 2019 [cited 2023 Aug 20]. Available from: https:\/\/www.parent.projectmd.org\/drug-development-pipeline\/pf-06939926-mini-dystrophin-gene-therapy\/"},{"key":"e_1_3_4_69_1","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics announces topline results from EMBARK a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. 2023 Oct 30 [cited 2023 Dec 28]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-topline-results-embark-global-0"},{"key":"e_1_3_4_70_1","unstructured":"REGENXBIO. Therapeutic pipeline: RGX-202 for Duchenne. REGENXBIO [Internet]. 2023 [cited 2023 Aug 12]. Available from: https:\/\/www.regenxbio.com\/therapeutic-programs\/rgx-202\/"},{"key":"e_1_3_4_71_1","volume-title":"Pfizer presents initial clinical data on phase 1b gene therapy study for Duchenne muscular dystrophy (DMD)","author":"Pfizer","year":"2019","unstructured":"Pfizer. Pfizer presents initial clinical data on phase 1b gene therapy study for Duchenne muscular dystrophy (DMD). Orlando, Florida: Pfizer; 2019."},{"key":"e_1_3_4_72_1","first-page":"77","volume-title":"MDA Clinical and Scientific Conference 2021","author":"Belluscio B","year":"2021","unstructured":"Belluscio B, Beaverson K, Garnier N, et al. Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: update on data from the phase 1b study. MDA Clinical and Scientific Conference 2021; 2021 [cited 2023 Aug 12]. p. 77. Available from: https:\/\/www.mdaconference.org\/abstract-library\/safety-and-efficacy-of-pf-06939926-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-update-on-data-from-the-phase-1b-study\/"},{"key":"e_1_3_4_73_1","unstructured":"Johnson V. PF-06939926 continues to show safety and efficacy in Duchenne muscular dystrophy. Neurology Live [Internet]. 2021 Apr 21 [cited 2023 Aug 13]; Available from: https:\/\/www.neurologylive.com\/view\/pf-06939926-safe-efficacious-dmd"},{"key":"e_1_3_4_74_1","unstructured":"Reinhard A. Patient death reported in phase 1b mini-dystrophin gene therapy trial in DMD. Neurology Live. 2021. [cited 2024 Feb 05]. Available from: https:\/\/www.neurologylive.com\/view\/patient-death-reported-phase-1b-mini-dystrophin-gene-therapy-trial-dmd"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.29211.bfs"},{"key":"e_1_3_4_76_1","unstructured":"Johnson V. High dose fordadistrogene movaparvovec improves NSAA muscle volume in patients with DMD. CGT Live. 2023 May 23;"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.162"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00687-z"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fopow.2021.03.008"},{"key":"e_1_3_4_80_1","unstructured":"Solid Biosciences. Solid biosciences announces updated corporate strategy to develop SGT-001 and SGT-003 pipeline programs for patients with duchenne muscular dystrophy. Global Newswire. 2022 Apr 22;"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.10.005"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00140-19"},{"key":"e_1_3_4_83_1","unstructured":"Genethon. Genethon announces first patient dosed in clinical trial of investigational gene therapy GNT 0004 for Duchenne muscular dystrophy [internet]. Genethon. 2021 [cited 2023 Oct 21]. Available from: https:\/\/www.genethon.com\/genethon-announces-first-patient-dosed-in-clinical-trial-of-investigational-gene-therapy-gnt-0004-for-duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_84_1","unstructured":"Genethon. Duchenne muscular dystrophy - our pipeline [Internet]. Genethon. 2023 [cited 2023 Oct 21]. Available from: https:\/\/www.genethon.com\/our-pipeline\/duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153837"},{"key":"e_1_3_4_86_1","unstructured":"Edgewise Therapeutics. Corporate presentation: August 2023 [internet]. 2023 [cited 2023 Aug 22]. Available from: https:\/\/s29.q4cdn.com\/148823924\/files\/doc_presentations\/2023\/Aug\/03\/ewtx-corporate-presentation_august-2023_vfinal.pdf"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169059"},{"key":"e_1_3_4_88_1","unstructured":"Grover N. Another myostatin program combusts but acceleron has plenty in the pipeline. Endpoints News [Internet]. 2020 Mar 10 [cited 2023 Oct 21]; Available from: https:\/\/endpts.com\/another-myostatin-program-combusts-but-acceleron-has-plenty-in-the-pipeline\/"},{"key":"e_1_3_4_89_1","unstructured":"Keown A. Roche Terminates myostatin inhibitor for DMD one year after pfizer did the same [Internet]. Biospace. 2019 [cited 2023 Oct 21]. Available from: https:\/\/www.biospace.com\/article\/roche-terminates-myostatin-inhibitor-for-dmd-one-year-after-pfizer-did-the-same\/"},{"key":"e_1_3_4_90_1","unstructured":"Schreiner G. Understanding the potential of Epicatechin. Parent project muscular dystrophy [internet]. Parent Project Muscular Dystrophy; 2015 [cited 2023 Aug 21]. Available from: https:\/\/www.parentprojectmd.org\/aiovg_videos\/understanding-the-potential-of-epicatechin-december-2015\/"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci-2022-025"},{"key":"e_1_3_4_92_1","volume-title":"American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting [Internet]","author":"Lee J","year":"2023","unstructured":"Lee J, Kim M, Jeon H, et al. An open-label, dose-escalation, phase 1a study to evaluate safety, tolerability, and exploratory efficacy of intravenous injection of allogenic early-passage mesenchymal stem cells (MSCs), derived from Wharton\u2019s jelly in the umbilical cord, in patients with Duchenne muscular dystrophy. American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting [Internet]. 2023 [cited 2023 Aug 22]. Available from: https:\/\/www.cgtlive.com\/view\/allogeneic-msc-therapy-demonstrates-safety-patients-duchenne-muscular-dystrophy"},{"key":"e_1_3_4_93_1","unstructured":"ENCell. Next generation stem cell therapeutics [internet]. ENCell Co. Ltd. 2023 [cited 2023 Aug 22]. Available from: http:\/\/encellinc.com\/?module=Html&action=SiteCompEn&sSubNo=8"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00012-5"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599820-000000000-00000"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.93"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S1666"},{"key":"e_1_3_4_99_1","volume-title":"Annual Parent Project Muscular Dystrophy Conference 2022 [Internet]","author":"Bettica P","year":"2022","unstructured":"Bettica P. Italfarmaco group announces positive topline data from phase 3 trial showing beneficial effect of givinostat in patients with Duchenne muscular dystrophy. Annual Parent Project Muscular Dystrophy Conference 2022 [Internet]. Businesswire; 2022 [cited 2023 Oct 18]. Available from: https:\/\/www.businesswire.com\/news\/home\/20220625005001\/en\/Italfarmaco-Group-Announces-Positive-Topline-Data-from-Phase-3-Trial-Showing-Beneficial-Effect-of-Givinostat-in-Patients-with-Duchenne-Muscular-Dystrophy"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104999"},{"key":"e_1_3_4_101_1","unstructured":"EspeRare. FDA has granted rare pediatric disease designation to Rimeporide. Geneva Switzerland: EspeRare; 2020. [cited 2024 Feb 05]. Available from: https:\/\/esperare.org\/en\/news\/archive\/202009"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1069-6"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.735912"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S93873"},{"key":"e_1_3_4_105_1","unstructured":"FDA. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy. US Food and Drug Administration [Internet]. 2023 Jun 22 [cited 2023 Dec 31]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy"},{"key":"e_1_3_4_106_1","first-page":"52","article-title":"The future of gene therapy","volume":"2","author":"McCain J","year":"2005","unstructured":"McCain J. The future of gene therapy. Biotechnol Healthc. 2005;2:52\u201360.","journal-title":"Biotechnol Healthc"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-01799-z"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803"},{"key":"e_1_3_4_109_1","unstructured":"FDA. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment guidance for industry [Internet]. 2018. Available from: https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttps:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2313105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:08:11Z","timestamp":1738202891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2313105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/13543784.2024.2313105"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2313105","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}